Deployment of in silico and in vitro Safety Assays in Early-Stage Drug Discovery
News Jul 20, 2012
One of the main reasons for the cost explosion in drug development is the increase in attrition, especially in highly expensive later-stage clinical trials. Between 1990 and 2004, attrition increased to 70% in Phase II and 50% in Phase III, and it is estimated that of all compounds that make it into the clinic, only 11% reach the market. Some of these later stage failures can be explained by a few factors: a shift in market potential; targets in a more complex biological context and lack of efficacy; and the need for new drugs with better efficacy or safety profile than the current standard of care. Toxicity, however, is the main reason for attrition, accounting for 30% of compound failure in clinical trials and 40–60% failure in preclinical work.
As such, the pharmaceutical industry is greatly interested in reducing costly late-stage attrition by shifting compound failure earlier in the R&D pipeline and, if possible, even before preclinical in vivo studies. In fact, the National Research Council in its 2007 report “Toxicity Testing in the 21st Century: A Vision and a Strategy” calls for transforming toxicology “from a system based on whole-animal testing to one founded primarily on in vitro methods that evaluate changes in biologic processes using cells, cell lines, or cellular components, preferably of human origin.” And indeed, using in vitro assays to assess compound-induced toxicity has a long history dating back more than half a century; for example, the use of cells to measure the toxicity of sulphonamide drugs was published in 1941.
The full article is published online in Future Medicinal Chemistry and is free to access.
Genes Can Influence the Mutation, Activity of Nearby GenesNews
Study shows that a gene’s neighborhood can influence whether and how the activity of a gene changes.READ MORE
Brain Regions Implicated in Mental Disorders Influenced by Neanderthal GenesNews
Findings indicate that the more a person’s genome carries genetic vestiges of Neanderthals, the more certain parts of his or her brain and skull resemble those of humans’ evolutionary cousins that went extinct 40,000 years ago.READ MORE
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017